Verastem Inc (VSTM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
41 Pages - GLDATA58278
$250.00

Summary

Verastem Inc (Verastem) is a biopharmaceutical company that discovers and develops drugs to treat cancer by the targeted killing of cancer stem cells. The company’s products include VS-6063, VS-4718 and VS-5584. Its VS-6063 is used for the treatment of lung cancer, mesothelioma, and ovarian cancer. Verastem’s VS-4718 and VS-5584 is used for the treatment of solid tumors and lymphomas. The company developed proprietary technology to create a stable population of CSCs that are suitable for use in high-throughput screening of small molecule compounds. It develops drugs that solve the problem of cancer recurrence and metastasis. Verastem is headquartered in Needham, Massachusetts, the US.

Verastem Inc (VSTM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Verastem Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Verastem Inc, Medical Devices Deals, 2010 to YTD 2016 9
Verastem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Verastem Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Verastem Secures US$20.1 Million In Series B-2 Financing 12
Verastem Secures US$32 Million In Series B Financing 13
Verastem Secures US$16 Million In Series A Round Of Financing 15
Partnerships 17
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 17
Merck, Pfizer and Verastem Enter into Agreement 18
Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 19
Licensing Agreements 20
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 20
Verastem Enters Into Licensing Agreement With Scripps Research Institute For VS-4718 22
Verastem Enters Into Licensing Agreement With Pfizer For VS-6063 24
Verastem Enters into Licensing Agreement with Poniard Pharma 26
Verastem Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 27
Verastem Enters into Licensing Agreement with Whitehead Institute for Biomedical Research to Treat Cancer 28
Equity Offering 30
Verastem USD54 Million in Public Offering of Shares 30
Verastem Files Registration Statement For Public Offering Of Common Stock For US$35 Million 32
Verastem Completes Public Offering Of Shares For US$63.8 Million 34
Verastem Completes IPO For US$63 Million 36
Verastem Inc - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Verastem Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Verastem Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Verastem Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Verastem Inc, Medical Devices Deals, 2010 to YTD 2016 9
Verastem Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Verastem Secures US$20.1 Million In Series B-2 Financing 12
Verastem Secures US$32 Million In Series B Financing 13
Verastem Secures US$16 Million In Series A Round Of Financing 15
Merck Sharp & Dohme, Verastem and Cancer Research UK Enter into Agreement 17
Merck, Pfizer and Verastem Enter into Agreement 18
Verastem Enters Into Research Agreement With Eisai For Small Molecule Wnt Inhibitors 19
Verastem Enters into Licensing Agreement with Infinity Pharma for Duvelisib 20
Verastem Enters Into Licensing Agreement With Scripps Research Institute For VS-4718 22
Verastem Enters Into Licensing Agreement With Pfizer For VS-6063 24
Verastem Enters into Licensing Agreement with Poniard Pharma 26
Verastem Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 27
Verastem Enters into Licensing Agreement with Whitehead Institute for Biomedical Research to Treat Cancer 28
Verastem USD54 Million in Public Offering of Shares 30
Verastem Files Registration Statement For Public Offering Of Common Stock For US$35 Million 32
Verastem Completes Public Offering Of Shares For US$63.8 Million 34
Verastem Completes IPO For US$63 Million 36
Verastem Inc, Key Competitors 38
Verastem Inc, Key Employees 39
Verastem Inc, Subsidiaries 40

List of Figures
Verastem Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Verastem Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Verastem Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Verastem Inc, Medical Devices Deals, 2010 to YTD 2016 9

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838